SCHEMBL319320

SCHEMBL319320

CCCCCC(C#N)C#N

nearest known ligand 0.46

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
OPRM1 P35372 1/20 0.42
LMNA P02545 1/20 0.39
DNM1 Q05193 2/20 0.38
THRB P10828 1/20 0.37
GPR84 Q9NQS5 6/20 0.37
FDPS P14324 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL486866 0.97 TSHR (0.43) TSHROPRM1LMNADNM1THRB
SCHEMBL28129612 0.97 TSHR (0.43) TSHROPRM1LMNADNM1THRB
SCHEMBL28129611 0.97 TSHR (0.43) TSHROPRM1LMNADNM1THRB
SCHEMBL3979603 0.97 TSHR (0.43) TSHROPRM1LMNADNM1THRB
SCHEMBL8044861 0.97 TSHR (0.43) TSHROPRM1LMNADNM1THRB
SCHEMBL3978555 0.97 TSHR (0.43) TSHROPRM1LMNADNM1THRB
SCHEMBL3142817 0.97 TSHR (0.43) TSHROPRM1LMNADNM1THRB
SCHEMBL27634401 0.97 TSHR (0.43) TSHROPRM1LMNADNM1THRB
SCHEMBL325130 0.92
Bicarbonate SCHEMBL11767455 0.87 GPR84 (0.52) TSHRGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970166-A1 METHOD OF MANUFACTURE OF OCTANEDIOIC ACID, PRECURSORS, AND DERIVATIVES Segetis, Inc. (US) 2016-01-20 EP claimed
CN-105189470-A Method of manufacture of octanedioic acid, precursors, and derivatives SEGETIS INC 2015-12-23 CN claimed
WO-2014150384-A1 METHOD OF MANUFACTURE OF OCTANEDIOIC ACID, PRECURSORS, AND DERIVATIVES SEGETIS, INC. (US) 2014-09-25 WO claimed
CN-102522590-A Non-aqueous organic electrolyte, lithium ion secondary battery containing non-aqueous organic electrolyte, preparation method of lithium ion secondary battery and terminal communication equipment HUAWEI TECH CO LTD 2012-06-27 CN claimed
JP-9124980-A None JP disclosed
US-20250309494-A1 BATTERY ZHUHAI COSMX BATTERY CO., LTD. (CN) 2025-10-02 US disclosed
US-12209184-B2 Asphalt additives ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) 2025-01-28 US disclosed
CN-116194547-B Nitrile solvent 奥升德功能材料运营有限公司 2024-12-27 CN disclosed
US-12006493-B2 Nitrile solvents ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) 2024-06-11 US disclosed
EP-4342009-A1 HIGH VOLUME MANUFACTURING OF ALLOY ANODES FOR LI-ION BATTERY Applied Materials, Inc. (US) 2024-03-27 EP disclosed
CN-114585673-B Asphalt additive 奥升德功能材料运营有限公司 2023-11-14 CN disclosed
CN-111936461-B Process for producing dicyanoalkane and bis (aminomethyl) alkane 三菱瓦斯化学株式会社 2023-09-05 CN disclosed
EP-1344774-A1 Synthesizing methods of dicyanomethylidene compound and heterocyclic compound FUJI PHOTO FILM CO., LTD. (JP) 2003-09-17 EP disclosed
US-20020058699-A1 Methods for treating seizure disorders by inhibiting MAPK pathway activation BAYLOR COLLEGE OF MEDICINE 2002-05-16 US disclosed
WO-2002002097-A2 METHODS FOR TREATING SEIZURE DISORDERS BY INHIBITING MAPK PATHWAY ACTIVATION WITH NITRILES SWEATT J DAVID (US) 2002-01-10 WO disclosed
EP-1163215-A1 AMINO-THIO-ACRYLONITRILES AS MEK INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-12-19 EP disclosed
CN-1303396-A Polymerization method KANEGAFUCHI CHEMICAL IND (JP) 2001-07-11 CN disclosed
US-6153784-A REMOVING THE HALIDE-CONTAINING PHASE-TRANSFER CATALYST, USED TO PREPARE NITRILES BY REACTING HALOALKANES AND METAL CYANIDES, BY HEATING; ADDING A BASE OF GROUP 1A METAL HYDROXIDES, CARBONATES OR BICARBONATES AND SEPARATING BASF AKTIENGESELLSCHAFT (DE) 2000-11-28 US disclosed
WO-2000056706-A1 AMINO-THIO-ACRYLONITRILES AS MEK INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-09-28 WO disclosed
JP-H09124980-A WATER-BASED RECORDING LIQUID FOR INK JET RECORDING FUJI PHOTO FILM CO LTD 1997-05-13 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058699-A1 Methods for treating seizure disorders by inhibiting MAPK pathway activation MAPKAPK2, MAPK1, MAPK4 TSHR 3602/4885OPRM1 2489/4885LMNA 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.